Tango Therapeutics
TNGX
21.83
-0.07
-0.32%
Tango Therapeutics
US · TNGX
#2322 by market cap
Listed 1970
21.83
-0.07
-0.32%
Live - 5344 symbols - heartbeat 224s ago
· 2026-10-08 08:28
Pre-market
21.71
-0.55%
After-hours
21.83
0.00%
- Market cap
- 3.68B
- P/E (TTM)i
- -25.99
- P/Bi
- 3.59
- EPSi
- -0.87
- Div yieldi
- 0.00%
- 52W posi
- 55%
Reader sentiment
Are you bullish or bearish on TNGX?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Mixed / stable
- The number of reporting institutions increased by 1 in the most recent period (2026/Q3).
- Total institutional ownership (as a % of shares) was little changed.
Institutional ownership
- Held by institutions
- 127.87% -0.08pp
- Institutions
- 292 +1
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions trimmed shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Hedge Fund51.47%
Mutual Fund48.92%
VC/PE Fund18.49%
Public Company7.97%
Individual/Insider1.07%
Private Company0.56%
Government Pension Fund0.23%
Insurance Company0.19%
Top holders as of 2026-06-30
RTW Investments, LP
8.24% · 13.90M sh
BlackRock
7.38% · 12.44M sh
FMR
7.31% · 12.33M sh
Farallon Capital Management, L.L.C.
7.28% · 12.28M sh
Boxer Capital Management, LLC
6.45% · 10.88M sh
The Goldman Sachs Group, Inc.
5.72% · 9.65M sh
TCG Crossover Management, LLC
5.39% · 9.08M sh
Vanguard Capital Management, LLC
4.08% · 6.87M sh
T. Rowe Price Group, Inc.
3.91% · 6.60M sh
Third Rock Ventures, LLC
3.90% · 6.57M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 25 buys · 22 sells
| Name | Role | Stake |
|---|---|---|
| Barbara Weber | Chief Executive Officer | 0.92% |
| Daniella Beckman | Chief Financial Officer | 0.08% |
| Mace Rothenberg | Independent Director | 0.02% |
| John Ketchum | Independent Director | 0.01% |
| Adam Crystal | President of Research & Development | 0.01% |
| Jessica Newcomb | -- | 0.01% |
| Lesley Calhoun | Independent Director | 0.01% |
| Malte Peters | Independent Director | 0.01% |
| Alexis Borisy | Independent Chairperson | 0.01% |
| Third Rock Ventures, LLC | -- | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-21 | Jessica Newcomb | -- | Automatic Disposition | -8,200 | $22.80–25.17 |
| 2026-08-31 | Adam Crystal | President of Research & Development | Derivative Exercise and Sale | -27,000 | $5.20–22.37 |
| 2026-08-02 | Adam Crystal | President of Research & Development | Derivative Exercise and Sale | -27,000 | $5.20–27.35 |
| 2026-06-30 | Adam Crystal | President of Research & Development | Derivative Exercise and Sale | -27,000 | $5.20–30.25 |
| 2026-06-18 | Robert Azelby | Independent Director | Other Acquisition | +5,740 | -- |
| 2026-06-18 | Robert Azelby | Independent Director | Other Derivative Acquisition | +35,910 | $27.97 |
| 2026-06-16 | Nextech Invest Ltd. | -- | Intent to Sell (Form 144) | -3,766,081 | $30.10 |
| 2026-06-10 | Daniella Beckman | Chief Financial Officer | Intent to Sell (Form 144) | -1,791,726 | $28.76 |
| 2026-06-09 | Daniella Beckman | Chief Financial Officer | Intent to Sell (Form 144) | -4,446 | $30.00 |
| 2026-06-04 | Mace Rothenberg | Independent Director | Other Acquisition | +4,000 | -- |
| 2026-06-04 | Mace Rothenberg | Independent Director | Other Derivative Acquisition | +25,000 | $20.22 |
| 2026-06-04 | Lesley Calhoun | Independent Director | Other Acquisition | +4,000 | -- |
| 2026-06-04 | Lesley Calhoun | Independent Director | Other Derivative Acquisition | +25,000 | $20.22 |
| 2026-06-04 | John Ketchum | Independent Director | Other Acquisition | +4,000 | -- |
| 2026-06-04 | John Ketchum | Independent Director | Other Derivative Acquisition | +25,000 | $20.22 |
| 2026-06-04 | Sung Lee | Director | Other Acquisition | +570 | -- |
| 2026-06-04 | Sung Lee | Director | Other Derivative Acquisition | +3,570 | $20.22 |
| 2026-05-31 | Adam Crystal | President of Research & Development | Derivative Exercise and Sale | -27,000 | $5.20–23.06 |
| 2026-04-30 | Adam Crystal | President of Research & Development | Derivative Exercise and Sale | -27,000 | $5.20–22.00 |
| 2026-04-30 | Matthew Gall | Chief Financial Officer | Other Acquisition | +40,000 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 08:28:53 · For reference only, not investment advice and not tailored to your situation.